Evidence map›Paper›PMID 24846384›Full record

ArticlemBio2014

Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses.

Vineet D Menachery, Amie J Eisfeld, Alexandra Schäfer, Laurence Josset, Amy C Sims, Sean Proll, Shufang Fan, Chengjun Li, Gabriele Neumann, Susan C Tilton and 16 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 1 synthesis or guideline pooled it, 296 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Targeting G9a-miScience · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. The Immune Response ofInternational journal of molecular sciences · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 2 countries.

Vineet D MenacheryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Amie J EisfeldInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Laurence JossetDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
Amy C SimsDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Sean ProllDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
Shufang FanInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Chengjun LiInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Gabriele NeumannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Susan C TiltonBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Jean ChangDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
Lisa E GralinskiDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Casey LongDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Richard GreenDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
Christopher M WilliamsDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
Jeffrey WeissDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
Melissa M MatzkeBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Bobbie-Jo Webb-RobertsonBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Athena A SchepmoesBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Anil K ShuklaBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Thomas O MetzBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Richard D SmithBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Katrina M WatersBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, USA.
Michael G Katze
Yoshihiro Kawaoka
Ralph S BaricRbaric@email.unc.edu.
Pacific Northwest National Laboratory · USUniversity of Washington · USUniversity of North Carolina at Chapel Hill · USUniversity of Wisconsin–Madison · USSocial Insurance Saitama Chuo Hospital · JP

Funding

Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HEISE, MARK T · 2012 to 2021
$36.6M
Systems Biology Identifies Restriction Factors for West Nile VirusU19AI106772 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI LIVNY, MIRON · 2013 to 2017
$26.1M
Equipment Supplement Request for a Research Resource for Ultra-sensitive High Throughput ProteomicsP41GM103493 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI SMITH, RICHARD D · 2012 to 2022
$22.6M
Evaluation of SARS-CoV 2'O Methyltransferase MutantsF32AI102561 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MENACHERY, VINEET D · 2013 to 2015
$132k
NIAID NIH HHS F32 AI102561NIAID NIH HHS F32AI102561NIAID NIH HHS HHSN272200800060CNIAID NIH HHS U19 AI100625NIAID NIH HHS U19AI100625NIAID NIH HHS U19 AI106772NIAID NIH HHS U19AI106772NIGMS NIH HHS 8 P41 GM103493-10NIGMS NIH HHS P41 GM103493
6 · The paper itself

Abstract

unlabelledThe broad range and diversity of interferon-stimulated genes (ISGs) function to induce an antiviral state within the host, impeding viral pathogenesis. While successful respiratory viruses overcome individual ISG effectors, analysis of the global ISG response and subsequent viral antagonism has yet to be examined. Employing models of the human airway, transcriptomics and proteomics datasets were used to compare ISG response patterns following highly pathogenic H5N1 avian influenza (HPAI) A virus, 2009 pandemic H1N1, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome CoV (MERS-CoV) infection. The results illustrated distinct approaches utilized by each virus to antagonize the global ISG response. In addition, the data revealed that highly virulent HPAI virus and MERS-CoV induce repressive histone modifications, which downregulate expression of ISG subsets. Notably, influenza A virus NS1 appears to play a central role in this histone-mediated downregulation in highly pathogenic influenza strains. Together, the work demonstrates the existence of unique and common viral strategies for controlling the global ISG response and provides a novel avenue for viral antagonism via altered histone modifications. IMPORTANCE: This work combines systems biology and experimental validation to identify and confirm strategies used by viruses to control the immune response. Using a novel screening approach, specific comparison between highly pathogenic influenza viruses and coronaviruses revealed similarities and differences in strategies to control the interferon and innate immune response. These findings were subsequently confirmed and explored, revealing both a common pathway of antagonism via type I interferon (IFN) delay as well as a novel avenue for control by altered histone modification. Together, the data highlight how comparative systems biology analysis can be combined with experimental validation to derive novel insights into viral pathogenesis.

Indexed as

Gene Expression RegulationAnimalsCell LineCluster AnalysisCoronavirusCoronavirus InfectionsGene Expression ProfilingHistonesHost-Pathogen InteractionsHumansInfluenza A virusInfluenza A Virus, H5N1 SubtypeInfluenza, HumanInterferonsInterferon Type IMiddle East Respiratory Syndrome CoronavirusHistonesINS1 protein, influenza virusInterferonsInterferon Type ITranscription FactorsViral Nonstructural Proteins

Identifiers

PMID24846384
PMCPMC4030454
OpenAlexW2103208261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.